TREM2 encodes plaque macrophage plasticity to mediate atherosclerosis regression
- 1Department of Integrative Biology and Physiology, University of Minnesota, Minneapolis, MN, USA
Abstract
Cholesterol lowering therapies stabilize atherosclerotic plaque and reduce ischemic events, but the molecular mechanisms governing plaque remodeling or regression remain poorly defined. The lipid sensor TREM2 is a key modulator of plaque-associated foam cell development and was upregulated by plaque macrophages in atherosclerosis regression. We examined macrophage- or monocyte-specific Trem2 deletion during regression in mice and found that TREM2 expression on plaque macrophages, not newly recruited monocytes, was required for plaque regression. Trem2 deletion impeded necrotic core resolution, leading us to interrogate the efferocytic capacity of TREM2+ cells during lipid lowering. An in vitro model of cholesterol-experienced ex-lipid associated macrophages (Ex-LAMs) demonstrated that prior lipid priming enhanced efferocytic ability after unloading lipids and maintained expression of lysosomal and cytoskeletal remodeling genes. Augmented TREM2 signaling through genetic models or agonist treatment accelerated efferocytic ability in vitro and plaque regression in vivo. Thus, we posit that a TREM2-dependent ExLAM programming drives atherosclerosis resolution and facilitates beneficial plaque remodeling through enhanced efferocytosis. Overall, targeting the TREM2 pathway may be a viable strategy for stabilizing atherosclerotic plaques in patients treated with aggressive cholesterol control.
Related
- Vascular Smooth Muscle Cell Plasticity in Atherosclerosis: From Macrophage-like Transdifferentiation to Therapeutic Targeting
- Macrophage PIM1 Drives Atherosclerosis by Enhancing Foam Cell Formation Via CD36
- USP20 Stabilizes FABP5 to Drive Macrophage Foam Cell Formation and Atherosclerosis
- BDH1 Attenuates Macrophage Foam Cell Formation and Inflammation in Atherosclerosis Via Modulating Histone H3K9 Acylation Balance and Activating PPAR Signaling.
- Calcineurin-mediated regulation of macrophage plasticity drives anti-tumor activity.
BibTeX
@misc{hillman2026trem2,
title = {{TREM2 encodes plaque macrophage plasticity to mediate atherosclerosis regression}},
author = {H. Hillman and G. M. Stuttgen and S.-J. Lee and M. T. Patterson and M. D. Chang and Y. Zhou and A. E. Kennedy and P. R. Schrank and O. Mitha and T. J. Barrett and M. Colonna and J. W. Williams},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.31.763330},
url = {https://www.biorxiv.org/content/10.64898/2026.10.31.763330v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - TREM2 encodes plaque macrophage plasticity to mediate atherosclerosis regression
AU - H. Hillman
AU - G. M. Stuttgen
AU - S.-J. Lee
AU - M. T. Patterson
AU - M. D. Chang
AU - Y. Zhou
AU - A. E. Kennedy
AU - P. R. Schrank
AU - O. Mitha
AU - T. J. Barrett
AU - M. Colonna
AU - J. W. Williams
PY - 2026
DA - 2026/10/31
PB - bioRxiv
DO - 10.64898/2026.10.31.763330
UR - https://www.biorxiv.org/content/10.64898/2026.10.31.763330v1
AB - Cholesterol lowering therapies stabilize atherosclerotic plaque and reduce ischemic events, but the molecular mechanisms governing plaque remodeling or regression remain poorly defined. The lipid sensor TREM2 is a key modulator of plaque-associated foam cell development and was upregulated by plaque macrophages in atherosclerosis regression. We examined macrophage- or monocyte-specific Trem2 deletion during regression in mice and found that TREM2 expression on plaque macrophages, not newly recruited monocytes, was required for plaque regression. Trem2 deletion impeded necrotic core resolution, leading us to interrogate the efferocytic capacity of TREM2+ cells during lipid lowering. An in vitro model of cholesterol-experienced ex-lipid associated macrophages (Ex-LAMs) demonstrated that prior lipid priming enhanced efferocytic ability after unloading lipids and maintained expression of lysosomal and cytoskeletal remodeling genes. Augmented TREM2 signaling through genetic models or agonist treatment accelerated efferocytic ability in vitro and plaque regression in vivo. Thus, we posit that a TREM2-dependent ExLAM programming drives atherosclerosis resolution and facilitates beneficial plaque remodeling through enhanced efferocytosis. Overall, targeting the TREM2 pathway may be a viable strategy for stabilizing atherosclerotic plaques in patients treated with aggressive cholesterol control.
ER -